{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:04:44Z","timestamp":1790395484203,"version":"4.1.0"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"suppl_1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,2,1]]},"DOI":"10.1093\/cid\/cir885","type":"journal-article","created":{"date-parts":[[2012,1,13]],"date-time":"2012-01-13T18:56:48Z","timestamp":1326481008000},"page":"S73-S78","source":"Crossref","is-referenced-by-count":148,"title":["Combination Therapy for Mucormycosis: Why, What, and How?"],"prefix":"10.1093","volume":"54","author":[{"given":"Brad","family":"Spellberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Roilides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russel E.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Petrikkos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios P.","family":"Kontoyiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,2,1]]},"reference":[{"key":"key\n\t\t\t\t20171013233036_bib1","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1128\/CMR.18.3.556-569.2005","article-title":"Novel perspectives on mucormycosis: pathophysiology, presentation, and management","volume":"18","author":"Spellberg","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20171013233036_bib2","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171013233036_bib3","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1128\/CMR.13.2.236-301.2000","article-title":"Zygomycetes in human disease","volume":"13","author":"Ribes","year":"2000","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20171013233036_bib4","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/339202","article-title":"Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients","volume":"34","author":"Marr","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171013233036_bib5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1086\/313803","article-title":"Zygomycosis in the 1990s in a tertiary-care cancer center","volume":"30","author":"Kontoyiannis","year":"2000","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171013233036_bib6","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1080\/10428190310001653691","article-title":"Improved outcome of zygomycosis in patients with hematological diseases?","volume":"45","author":"Gleissner","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"key\n\t\t\t\t20171013233036_bib7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/13693780903311944","article-title":"Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases","volume":"48","author":"Shoham","year":"2009","journal-title":"Med Mycol"},{"key":"key\n\t\t\t\t20171013233036_bib8","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1086\/599105","article-title":"Recent advances in the management of mucormycosis: from bench to bedside","volume":"48","author":"Spellberg","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171013233036_bib9","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1128\/AAC.00456-09","article-title":"Efficacy of liposomal amphotericin B combined with gamma interferon or granulocyte-macrophage colony-stimulating factor for treatment of systemic zygomycosis in mice","volume":"53","author":"Rodriguez","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233036_bib10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-137-2-200207160-00008","article-title":"Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS","volume":"137","author":"Johnson","year":"2002","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20171013233036_bib11","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1097\/00002030-199712000-00010","article-title":"Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis","volume":"11","author":"Leenders","year":"1997","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171013233036_bib12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/jac\/30.4.535","article-title":"Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients","volume":"30","author":"Moreau","year":"1992","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171013233036_bib13","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2141.1997.2473063.x","article-title":"A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients","volume":"98","author":"Prentice","year":"1997","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20171013233036_bib14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/clinids\/22.2.315","article-title":"Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS","volume":"22","author":"Sharkey","year":"1996","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171013233036_bib15","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1600-0609.2004.00239.x","article-title":"Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies\u2014a randomized, controlled trial","volume":"72","author":"Subira","year":"2004","journal-title":"Eur J Haematol"},{"key":"key\n\t\t\t\t20171013233036_bib16","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"340","author":"Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171013233036_bib17","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1128\/AAC.47.10.3343-3344.2003","article-title":"Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae","volume":"47","author":"Ibrahim","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233036_bib18","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph\/ABLC Collaborative Study Group","volume":"31","author":"Wingard","year":"2000","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171013233036_bib19","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1086\/589857","article-title":"Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis","volume":"47","author":"Reed","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171013233036_bib20","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1086\/315643","article-title":"Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system","volume":"182","author":"Groll","year":"2000","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20171013233036_bib21","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1128\/AAC.45.12.3487-3496.2001","article-title":"Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study","volume":"45","author":"Walsh","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233036_bib22","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1128\/AAC.49.2.721-727.2005","article-title":"Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis","volume":"49","author":"Ibrahim","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233036_bib23","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1128\/AAC.49.2.830-832.2005","article-title":"Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice","volume":"49","author":"Spellberg","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233036_bib24","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1128\/AAC.01458-07","article-title":"Combination echinocandin-polyene treatment of murine mucormycosis","volume":"52","author":"Ibrahim","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233036_bib25","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.beha.2004.09.002","article-title":"Iron-chelating therapy with the new oral agent ICL670 (Exjade)","volume":"18","author":"Cappellini","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"key":"key\n\t\t\t\t20171013233036_bib26","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1172\/JCI32338","article-title":"The iron chelator deferasirox protects mice from mucormycosis through iron starvation","volume":"117","author":"Ibrahim","year":"2007","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t20171013233036_bib27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1128\/AAC.00792-10","article-title":"Activity of deferasirox in Mucorales: influences of species and exogenous iron","volume":"55","author":"Lewis","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233036_bib28","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1128\/AAC.01065-06","article-title":"Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis","volume":"50","author":"Reed","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233036_bib29","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.1768.1768","volume-title":"Long-term safety and tolerability of the once-daily, oral iron chelator deferasirox (Exjade, ICL670) in patients with transfusional iron overload. Abstract 896","author":"Cappellini","year":"2006"},{"key":"key\n\t\t\t\t20171013233036_bib30","article-title":"The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study: a randomized, double-blinded, placebo-controlled trial","author":"Spellberg","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171013233036_bib31","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","article-title":"A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia","volume":"107","author":"Cappellini","year":"2006","journal-title":"Blood"},{"key":"key\n\t\t\t\t20171013233036_bib32","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ajh.21119","article-title":"Clinical application of deferasirox: practical patient management","volume":"83","author":"Vichinsky","year":"2008","journal-title":"Am J Hematol"},{"key":"key\n\t\t\t\t20171013233036_bib33"},{"key":"key\n\t\t\t\t20171013233036_bib34","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1128\/AAC.01611-07","article-title":"Failure of deferasirox, an iron chelator agent, combined with antifungals in a case of severe zygomycosis","volume":"52","author":"Soummer","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233036_bib35","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1128\/AAC.46.5.1581-1582.2002","article-title":"In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes","volume":"46","author":"Sun","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233036_bib36","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1128\/AAC.46.4.1032-1037.2002","article-title":"Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000","volume":"46","author":"Pfaller","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233036_bib37","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1128\/AAC.00452-07","article-title":"In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents","volume":"51","author":"Almyroudis","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233036_bib38","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1128\/AAC.00662-08","article-title":"Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing","volume":"52","author":"Lass-Florl","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233036_bib39","first-page":"1","article-title":"Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus","volume":"12","author":"Arikan","year":"2008","journal-title":"Med Mycol"},{"key":"key\n\t\t\t\t20171013233036_bib40","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1128\/AAC.50.2.658-666.2006","article-title":"Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection","volume":"50","author":"Ullmann","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233036_bib41","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1128\/AAC.00454-06","article-title":"Posaconazole plasma concentrations in juvenile patients with invasive fungal infection","volume":"51","author":"Krishna","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233036_bib42","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1592\/phco.27.12.1627","article-title":"Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease","volume":"27","author":"Krishna","year":"2007","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20171013233036_bib43","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1128\/AAC.00939-09","article-title":"Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults","volume":"53","author":"Lebeaux","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233036_bib44","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1128\/AAC.48.1.137-142.2004","article-title":"Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis","volume":"48","author":"Andes","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233036_bib45","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1128\/AAC.46.7.2310-2312.2002","article-title":"In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model","volume":"46","author":"Sun","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233036_bib46","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1128\/AAC.47.11.3647-3650.2003","article-title":"Activity of posaconazole in treatment of experimental disseminated zygomycosis","volume":"47","author":"Dannaoui","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233036_bib47","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1128\/AAC.00628-08","article-title":"Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae","volume":"52","author":"Rodriguez","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233036_bib48","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1128\/AAC.01124-08","article-title":"Posaconazole mono- or combination therapy for treatment of murine zygomycosis","volume":"53","author":"Ibrahim","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233036_bib49","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1128\/AAC.01530-08","article-title":"In vitro activity of isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing","volume":"53","author":"Perkhofer","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233036_bib50","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1128\/AAC.01601-08","article-title":"Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect","volume":"53","author":"Warn","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233036_bib51","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1179\/joc.2009.21.3.272","article-title":"In vitro antifungal activity of isavuconazole against 345 Mucorales isolates collected at study centers in eight countries","volume":"21","author":"Verweij","year":"2009","journal-title":"J Chemother"},{"key":"key\n\t\t\t\t20171013233036_bib52","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1128\/AAC.01577-10","article-title":"Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins","volume":"55","author":"Ibrahim","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233036_bib53","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/MPH.0b013e3181ca0dcf","article-title":"Successful triple combination therapy of disseminated Absidia corymbifera infection in an adolescent with osteosarcoma","volume":"32","author":"Roux","year":"2010","journal-title":"J Pediatr Hematol Oncol"},{"key":"key\n\t\t\t\t20171013233036_bib54","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3201\/eid1509.090334","article-title":"Increasing incidence of zygomycosis (mucormycosis), France, 1997\u20132006","volume":"15","author":"Bitar","year":"2009","journal-title":"Emerg Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/54\/suppl_1\/S73\/20911193\/cir885.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T18:36:58Z","timestamp":1593542218000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/54\/suppl_1\/S73\/285939\/Combination-Therapy-for-Mucormycosis-Why-What-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,1]]},"references-count":54,"journal-issue":{"issue":"suppl_1","published-online":{"date-parts":[[2012,2,1]]},"published-print":{"date-parts":[[2012,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cir885","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2012,2,1]]},"published":{"date-parts":[[2012,2,1]]}}}